Whether you are an early-stage startup seeking foundational technology or a later-stage company seeking a new product or new technology, your session may include questions about what you might consider when you want to license technology. Some potential areas to discuss include university in-licenses, pharma out-licenses and collaborations, and how your business plan affects your licensing ambitions.
Need to know more about licensing technology for your company? Apply to meet one-on-one with Mark Wicker, JD, Partner at Perkins Coie.
Our expert consults are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.
If you choose a timeslot, we will require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows.
If you find that you are unable to attend, you may request a refund up to 5 days in advance. (This will give us time to offer the slot to the first person on the waitlist.) We regret that we cannot honor requests made at a later time.
Where & When
Zoom Meeting
Thursday, March 24, 2022
Apply by EOD Tuesday, March 15.
Mark Wicker, a partner in the Technology, Transactions & Privacy practice of Perkins Coie, advises clients in all aspects of acquiring, developing, commercializing and licensing new technologies and products. He has significant experience structuring strategic alliances, collaborations, joint ventures, licenses, and research, development, manufacturing and distribution relationships, often using novel approaches and pioneering methods that further his clients’ business objectives. His clients range from startups to well-established firms in the life sciences, technology, wireless, social media, clean technology, chemical and material sciences industries.
During his many years of practice, Mark has built a reputation for developing sophisticated business models and formulating business-centric legal solutions to the complex challenges biotechnology and life sciences companies face as they bring novel therapeutics and diagnostics to market. He also works in tandem with colleagues in the area of intellectual property and patent litigation to develop adversarial licensing programs and to negotiate settlement and key licensing agreements. Additionally, Mark has significant corporate experience in such areas as venture capital financing, public securities offerings, and mergers and acquisitions.
Mark regularly speaks and offers commentary on life sciences and technology issues, including startup capital raising and formation and licensing transactions.